Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

PUMA Aktie 481322 / DE0006969603

11.11.2025 16:00:03

EQS-News: PUMA shifts to licensing model with United Legwear Company LLC in the US and Canada

EQS-News: PUMA SE / Key word(s): Miscellaneous
PUMA shifts to licensing model with United Legwear Company LLC in the US and Canada

11.11.2025 / 16:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

PRESS RELEASE

 

PUMA shifts to licensing model with United Legwear Company LLC in the US and Canada 

Herzogenaurach, November 11, 2025 – Sports company PUMA will move from a business partnership to a licensing agreement structure with its long-term partner United Legwear Company LLC (ULAC) that allows the company to sell PUMA branded products, mainly socks and underwear, but also including children’s apparel and accessories in the United States and Canada. This change took effect on November 1, 2025.

Previously, PUMA and United Legwear Company LLC had a partnership, PUMA United, which focused on the sale of these products in the U.S. and Canada. PUMA held a 51% capital share in PUMA United. The products sold by PUMA United were manufactured, transported, and stored by United Legwear and its suppliers.

The move from a partnership to an exclusive licensing agreement is part of PUMA’s strategic initiative to reduce complexity within its operating model in North America and sharpen the focus on its core business in the region. It further solidifies the continued close partnership between PUMA and ULAC which has existed for 25 years. As outlined during its third-quarter results on October 30, PUMA is executing a reset and is optimizing its distribution network. At that stage, PUMA had already said it was considering a shift to a licensing model with United Legwear. Financial details of the new licensing agreement with United Legwear are not disclosed.

This transition to a licensing model aligns with market practices in North America, where the production and sale of such products are typically licensed to third parties. Through this shift, PUMA aims to create a leaner, more efficient business model while maintaining a strong brand presence in these categories via its valued long-term licensing partner. The transition also enhances transparency for investors and the capital market by enabling clearer financial reporting.

As a result of this change, PUMA United will be classified as a discontinued operation in PUMA’s financial reporting from November of 2025 onwards. Accordingly, current year and prior-period figures will be restated, with PUMA United’s results, assets, and liabilities presented separately from continuing operations. Sales generated by the partnership amounted to €427.9 million, while net earnings attributable to non-controlling interests were €60.7 million for the 2024 financial year. For additional information regarding disclosures on non-controlling interests, please refer to page 315 of the PUMA Annual Report 2024.

Media Contact: Robert-Jan Bartunek – PUMA Corporate Communications – robert.bartunek@puma.com

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.



11.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: PUMA SE
PUMA WAY 1
91074 Herzogenaurach
Germany
Phone: +49 9132 81 0
Fax: +49 9132 81 42375
E-mail: investor-relations@puma.com
Internet: www.puma.com
ISIN: DE0006969603
WKN: 696960
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 2227872

 
End of News EQS News Service

2227872  11.11.2025 CET/CEST

Analysen zu PUMA SE

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
07:16 PUMA Sector Perform RBC Capital Markets
05.11.25 PUMA Halten DZ BANK
03.11.25 PUMA Neutral UBS AG
31.10.25 PUMA Buy Goldman Sachs Group Inc.
31.10.25 PUMA Hold Deutsche Bank AG
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’193.40 19.16 SJ6B5U
Short 13’444.90 13.69 U2TBSU
Short 13’930.53 8.90 SY9BNU
SMI-Kurs: 12’702.08 11.11.2025 17:30:12
Long 12’163.68 19.77 SO2B2U
Long 11’889.18 13.84 SZDBEU
Long 11’379.10 8.90 SPMBUU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Aktien in diesem Artikel

PUMA SE 112.30 2.23% PUMA SE